erk inhibitor ii

ERK Inhibitor II (Negative control) effectively blocks extracellular signal-regulated kinase (ERK) activity and interferes with insulin receptor activation, serving as a valuable tool in diabetes research.

GL-V9 is an AMPK activator, protecting against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy.

SIJ1777 is a pyrimidopyrimidinone class type II pan-BRAF inhibitor, optimized as a derivative of GNF-7. It exerts anti-tumor effects by simultaneously inhibiting the phosphorylation and activation of the MAPK pathway (MEK/ERK) and the PI3K/AKT pathway. The core advantage of SIJ1777 is its ability to maintain double-digit nanomolar GI50 values against class II/III BRAF mutants (non-V600 mutants) and NRAS-mutant melanoma cells that are insensitive to current clinical drugs (such as vemurafenib, PLX8394), effectively inducing apoptosis and blocking tumor cell migration and anchorage-independent growth.

RMC-4791 is a RAS(ON) multi-selective tri-complex inhibitor (TCI) that binds the KRAS switch II region differently from daraxonrasib, with reduced dependence on the Y64 interaction. This enables RMC-4791 to retain inhibitory activity against KRAS Y64 resistance mutants and effectively suppress ERK signaling and cell proliferation, highlighting its potential to overcome daraxonrasib resistance.

1. Atractylenolide II (2-Atractylenolide) has antimelanoma effect by inhibiting STAT3 signalling. 2. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation , ERK and Akt inactivation, p53 dependent.